Cancer has the ability to extend through the lymphatic system and invade lymph nodes. In that situation, the prognosis is worse than when the tumor remains confined to the primary organ. For that reason, oncologic surgeons have advocated the removal of lymph nodes to achieve better staging for counselling and clinical decision-making regarding follow-up and administration of adjuvant therapy. The curative role of lymphadenectomy in most cancers remains, however, controversial.

This activity seeks to provide a comprehensive and effective platform for discussion of the latest advances in the detection and treatment of lymph node and distant metastasis through state-of-the-art lectures by internationally recognized experts.

The following educational gaps between recent urologic research and its integration into professional practice will be covered:

- Indication and role of imaging in the detection of lymph node metastasis.
- Indication, benefits and risks of lymphadenectomy in prostate, bladder, kidney and penis cancer.
- Update on the novel options for personalizing treatment and sequencing therapies for metastatic prostate, bladder, and kidney cancer.

Contact
Department of Urology
Comprehensive Cancer Center
Medical University of Vienna / Vienna General Hospital
Waehringer Guertel 18-20
1090 Vienna, Austria
Phone: +43 (0)1 40400 – 26150
Fax: +43 (0)1 40400 – 23320
E-Mail: shahrokhs.ariat@meduniwien.ac.at
http://controversies-urologic-oncology.com

www.meduniwien.ac.at/urologie

2nd Michael J. Marberger (MJM) Annual Meeting
Lymphadenectomy for urologic cancers: challenges and controversies
16th December 2016, 1.00 – 6.00 pm
Medical University of Vienna / Van Swieten Saal

www.meduniwien.ac.at/urologie
Program

1.00 – 1.10 pm
Welcome
Michael J. Marberger (Em.) and Shahrokh F. Shariat, Department of Urology, Medical University of Vienna, Vienna General Hospital, Austria

1.10 – 2.30 pm
Session 1. Prostate cancer
Lymphadenectomy in prostate cancer: extended, standard, limited, or not at all?
Axel Heidenreich, University Clinic of Urology, University Hospital Cologne, Germany

Lymph node imaging for prostate cancer: what changes my clinical strategy?
Pascal Baltzer, Department of Biomedical Imaging and Image-guided Therapy, Medical University of Vienna, Vienna General Hospital, Austria

Next generation sequencing to determine the clonal origin of lymph node metastasis in multifocal prostate cancer: Defining the biologically dominant nodule
Ganesh Palapattu, Division of Urologic Oncology, University of Michigan Health System, USA

What is new and hot in metastatic prostate cancer?
Gero Kramer, Department of Urology, Medical University of Vienna, Vienna General Hospital, Austria

2.30 – 3.00 pm
Coffee break

3.00 – 4.20 pm
Session 2. Penile and urothelial cancer
Lymphadenectomy in penile cancer: when and how?
Mesut Remzi, Department of Urology, Korneuburg, Austria

Lymphadenectomy in bladder cancer: extended, standard, or limited?
Marek Babjuk, Department of Urology, 2nd Faculty of Medicine, Charles University, Czech Republic

Lymphadenectomy in upper tract urothelial cancer: therapeutic value and templates
Tobias Klatte, Department of Urology, Medical University of Vienna, Vienna General Hospital, Austria

What is new and hot in metastatic urothelial cancer?
Maria DeSantis, Warwick Medical School, University of Warwick, England

4.20 – 4.50 pm
Coffee break

4.50 – 5.55 pm
Session 3. Kidney cancer
Lymphadenectomy in kidney cancer: when and why?
Agostino Mattei, Department of Urology, Kanton Hospital Luzern, Switzerland

What is new and hot in metastatic kidney cancer?
Manuela Schmidinger, Division of Oncology, Department of Medicine I, Medical University of Vienna, Vienna General Hospital, Austria

MJM Lecture: A glimpse in the future of urologic oncology
Axel Heidenreich, University Clinic of Urology, University Hospital Cologne, Germany

6.00 pm
Goodbye and farewell
Michael J. Marberger (Em.), Department of Urology, Medical University of Vienna, Vienna General Hospital, Austria